益肺清化颗粒联合化疗用于中晚期非小细胞肺癌的临床观察

摘要

OBJECTIVE:To observe the clinical efficacy and safety of Yifei qinghua granules combined with chemotherapy in the treatment of middle-advanced non-small cell lung cancer (NSCLC). METHODS:100 patients with middle-advanced NSCLC were selected and divided into control group and observation group according to random number table,with 50 cases in each group. Control group received vinorelbine+cisplatin or gemcitabine+cisplatin chemotherapy;observation group was additionally giv-en Yifei qinghua granules 20 g dissolved in 200 ml warm water orally,tid,on the basis of control group. TCM syndrome integral were observed in 2 group before and after treatment,KPS score and SF-36 scale were used to evaluate the quality of life. The lev-els of TNF-α and sIL-2R clinical efficacies and the occurrence of ADR were compared between 2 groups. RESULTS:Total effec-tive rate of observation group was 94.0%,which was significantly higher than 78.0% of control group,with statistical significance (P0.05). After treatment,TCM syndrome score,KPS score and SF-36 scale,the levels of TNF-α in 2 groups were increased significantly,and the observation group was significantly higher than the control group;the level of sIL-2R in 2 groups were decreased significantly,and the obcervation group was significantly lower than the con-trol group,with statistical significance (P<0.05). The incidence of nausea and vomiting,myelosuppression,alopecia in observa-tion group were significantly lower than in control group,with statistical significance (P<0.05). CONCLUSIONS:Yifei qinghua granules combined with chemotherapy is effective in the treatment of middle-advanced NSCLC,can promote the quality of life with good safety.%目的：观察益肺清化颗粒联合化疗用于中晚期非小细胞肺癌的临床疗效及安全性。方法：选取中晚期非小细胞肺癌患者100例，按随机数字表法分为对照组和观察组，各50例。对照组患者给予长春瑞滨+顺铂或吉西他滨+顺铂化疗；观察组患者在对照组基础上加用益肺清化颗粒20 g溶于温水200 ml冲服，tid。观察两组患者治疗前后中医证候评分、卡氏（KPS）评分、生存质量量表（SF-36）评分评估患者生存质量，比较两组患者肿瘤坏死因子α（TNF-α）和可溶性白细胞介素-2受体（sIL-2R）水平，并比较两组患者临床疗效及不良反应发生情况。结果：观察组患者临床总有效率为94.0％，显著高于对照组的78.0％，差异有统计学意义（P＜0.05）。治疗前，两组患者中医证候评分、KPS评分、SF-36量表评分及TNF-α和sIL-2R水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者中医证候积分、KPS评分、SF-36量表评分及TNF-α水平均显著升高，且观察组显著高于对照组；而sLR-2R水平显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者恶心呕吐、骨髓抑制、脱发、腹泻的发生率显著低于对照组，差异有统计学意义（P＜0.05）。结论：益肺清化颗粒联合化疗治疗中晚期非小细胞肺癌效果显著，能有效改善患者生存质量，且安全性较好。